LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Closed

SectorHealthcare

20.07 0.65

Buy Sell

Overview

Share price change

24h

Current

Min

19.3

Max

20.18

Key metrics
By Trading Economics
Income	4.8M -36M
Sales	6.1M 116M
Profit margin	-30.977
Employees	1,869
EBITDA	24M -31M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+110.93% upside

Dividends
By Dow Jones
Next Earnings	26 lut 2026

Market Stats
By TradingEconomics
Market Cap	-766M 2.2B
Previous open	19.42
Previous close	20.07

News Sentiment

By Acuity

25%

75%

62 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

28.13 / 31.12 Support & Resistance

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 lut 2026, 22:31 UTC

Earnings

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 lut 2026, 22:18 UTC

Earnings

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 lut 2026, 22:11 UTC

Earnings

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 lut 2026, 21:52 UTC

Earnings

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 lut 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 lut 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 lut 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 lut 2026, 23:34 UTC

Market Talk

Earnings

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 lut 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 lut 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 lut 2026, 22:45 UTC

Earnings

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 lut 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 lut 2026, 22:37 UTC

Earnings

Nutrien 4Q EPS $1.18 >NTR.T

18 lut 2026, 22:37 UTC

Earnings

Nutrien 4Q Sales $5.34B >NTR.T

18 lut 2026, 22:35 UTC

Earnings

Pan American Silver 4Q EPS $1.07 >PAAS

18 lut 2026, 22:35 UTC

Earnings

Pan American Silver 4Q Rev $1.18B >PAAS

18 lut 2026, 22:30 UTC

Earnings

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 lut 2026, 22:29 UTC

Earnings

Kinross Gold 4Q EPS 75c >K.T

18 lut 2026, 22:22 UTC

Earnings

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 lut 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 lut 2026, 22:16 UTC

Earnings

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 lut 2026, 22:05 UTC

Earnings

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 lut 2026, 22:03 UTC

Earnings

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 lut 2026, 22:02 UTC

Earnings

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 lut 2026, 22:02 UTC

Earnings

Kaiser Aluminum 4Q Sales $929M >KALU

18 lut 2026, 22:02 UTC

Earnings

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 lut 2026, 22:00 UTC

Earnings

Kinross Gold 4Q Adj EPS 67c >KGC

18 lut 2026, 22:00 UTC

Earnings

Kinross Gold 4Q Sales $2.02B >KGC

18 lut 2026, 21:56 UTC

Earnings

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 lut 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

110.93% upside

12 Months Forecast

Average 42.25 USD 110.93%

High 58 USD

Low 35 USD

Based on 4 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

62 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.